AJMC September 18, 2024
The Inflation Reduction Act was signed into law on August 16, 2022, and the debate over its Medicare-related benefits and impact on the prescription drug market has been raging ever since.
Among the financial benefit tenets of the Inflation Reduction Act (IRA) as they relate to the medical field and Medicare are that it lowers prescription drug costs through price negotiation, improves access to affordable care for millions, and helps to reduce the impact of inflation.1
At the same time, there are no fewer than 6 lawsuits currently pending against the IRA, filed by Merck, the US Chamber of Commerce, Bristol Myers Squibb, Pharmaceutical Research and Manufacturers of America, Astellas Pharma, and Johnson & Johnson. The lawsuits allege that the...
Today's Sponsors
Today's Sponsor